Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences has extended the lock-up period on shares held by directors, officers, and pre-IPO investors until January 31, 2027. This move underscores confidence as the company advances its Phase III clinical trial for GP2 immunotherapy targeting breast cancer recurrence prevention. The board retains flexibility to modify lock-up terms t…